Telix Pharmaceuticals Limited announced that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5, 2023 to December 9, 2023. Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5 pm CT on Wednesday December 6, 2023. The primary objective of the OPALESCENCE study was to evaluate how CAIX-targeted imaging with PET can be utilised for the diagnosis and staging of TNBC and to develop a deeper understanding of CAIX as a potential therapeutic target in this patient population with a significant unmet medical need.